Compare Abeona Therapeutics Inc (ABEO) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Tyson Foods, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Tyson Foods, Inc. trades at $58.65 (market cap $20.71B). The key difference: Tyson Foods, Inc. is far larger — about 55.5× Abeona Therapeutics Inc's market cap, and Tyson Foods, Inc. pays a 3.47% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TSN | |
|---|---|---|
Market Cap | $373.32M | $20.71B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $68.75 |
52-Week Low | $4.17 | $50.72 |
Enterprise Value | $228.22M | $28.30B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Tyson Foods (TSN) trades at $58.82, down 0.12% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results pending. Revenue for 2025 was $54.44 billion, with a net income margin of 0.81%. Recent news highlights innovation in prepared foods and new product launches, while analyst consensus is a Buy with a $69.75 price target.
The outlook for TSN is cautiously optimistic, supported by analyst bullishness and strategic growth in value-added products. Key opportunities include strong free cash flow guidance and debt reduction. Risks involve volatile cattle prices, inflationary pressures, and competitive market dynamics. The stock presents a potential upside from current levels, contingent on execution of long-term growth strategies and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
